KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Clinical trial NCT07232602 · RECRUITING
Trial details
- NCT number
- NCT07232602
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-09
- Primary completion
- 2031-07-08
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.